infigratinib
Selected indexed studies
- Infigratinib. (, 2006) [PMID:34554663]
- Infigratinib. (, 2012) [PMID:36592394]
- Infigratinib for cholangiocarcinoma. (Drugs Today (Barc), 2022) [PMID:35851868]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Infigratinib. (2006) pubmed
- Infigratinib. (2012) pubmed
- Infigratinib for cholangiocarcinoma. (2022) pubmed
- Infigratinib: First Approval. (2021) pubmed
- Oral Infigratinib Therapy in Children with Achondroplasia. (2025) pubmed
- Infigratinib Phosphate. (2021) pubmed
- Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia. (2025) pubmed
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. (2021) pubmed
- Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements. (2023) pubmed
- Infigratinib Approved for Cholangiocarcinoma. (2021) pubmed